Literature DB >> 28326824

Osteopontin: its potential role in cancer of children and young adults.

Gabrielle Karpinsky1, Aleksandra Fatyga2, Malgorzata Anna Krawczyk3, Madeleine Chamera4, Natalia Sande4, Dagmara Szmyd5, Ewa Izycka-Swieszewska6, Ewa Bien3.   

Abstract

OBJECTIVE: Osteopontin (OPN) is aglyco-phosphoprotein, involved in tissue remodeling, inflammation and boneresorption. In various adult neoplasms OPN was shown to correlate with cancer progression, invasiveness and metastasis. AIM: to define the role of OPN in malignancies of children and young adults.
MATERIAL AND METHODS: a structured PubMed and Google Scholar literature analysis based on reports published in English between I'1995 and XII'2015.
RESULTS: 14 studies (four on hematological malignancies, four on bone tumors, three on CNS tumors, two on dendritic proliferative diseases and one on renal tumors) were identified. Higher levels of serum and cerebro-spinal fluid OPN protein, and high expressions of OPN mRNA and SPP1 gene were present in more aggressive and advanced childhood malignancies. In children with acute lymphoblastic leukemia with CNS involvement and with atypical teratoid/rhabdoid tumor (AT/RT) and medulloblastoma, the serum and CSF OPN levels reflected tumor bulk and response to therapy, while in children with AT/RT and multisystem Langerhans cell histiocytosis with high-risk organs involvement, high OPN serum levels correlated with poorer survival. To the contrary, in osteosarcoma, high OPN mRNA and SPP1 gene expressions correlated with better survival and good response to chemotherapy.
CONCLUSIONS: The literature review suggests that OPN may play important roles in the development and progression of selected cancers of children and young adults, including acute lymphoblastic leukemia, malignant gliomas, AT/RT and Langerhans cell histiocytosis. However, limited number of published studies prevents from definite concluding on the clinical utility of OPN as a marker of diagnosis, prognosis and treatment monitoring in these pediatric cancers. Further studies performed in more numerous groups of patients with particular types of cancers of children and young adults are warranted.

Entities:  

Keywords:  Langerhans cell histiocytosis; SPP1 gene; brain tumors; childhood cancers; leukemia; lymphoma; osteopontin; osteosarcoma; prognostic marker; sialoprotein-1

Mesh:

Substances:

Year:  2017        PMID: 28326824     DOI: 10.2217/bmm-2016-0308

Source DB:  PubMed          Journal:  Biomark Med        ISSN: 1752-0363            Impact factor:   2.851


  5 in total

1.  Increased expression of osteopontin indicates poor prognosis in hepatocellular carcinoma.

Authors:  Honghai Wang; Donghui Guo; Junjie Li; Baolong Wei; Hong Zheng
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

Review 2.  A narrative review of central nervous system involvement in acute leukemias.

Authors:  Dalma Deak; Nicolae Gorcea-Andronic; Valentina Sas; Patric Teodorescu; Catalin Constantinescu; Sabina Iluta; Sergiu Pasca; Ionut Hotea; Cristina Turcas; Vlad Moisoiu; Alina-Andreea Zimta; Simona Galdean; Jakob Steinheber; Ioana Rus; Sebastian Rauch; Cedric Richlitzki; Raluca Munteanu; Ancuta Jurj; Bobe Petrushev; Cristina Selicean; Mirela Marian; Olga Soritau; Alexandra Andries; Andrei Roman; Delia Dima; Alina Tanase; Olafur Sigurjonsson; Ciprian Tomuleasa
Journal:  Ann Transl Med       Date:  2021-01

3.  Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor.

Authors:  Gabrielle Karpinsky; Malgorzata A Krawczyk; Ewa Izycka-Swieszewska; Aleksandra Fatyga; Agnieszka Budka; Walentyna Balwierz; Grazyna Sobol; Beata Zalewska-Szewczyk; Magdalena Rychlowska-Pruszynska; Teresa Klepacka; Bozenna Dembowska-Baginska; Bernarda Kazanowska; Anna Gabrych; Ewa Bien
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-13       Impact factor: 4.553

Review 4.  Osteopontin at the Crossroads of Inflammation and Tumor Progression.

Authors:  Luigi Mario Castello; Davide Raineri; Livia Salmi; Nausicaa Clemente; Rosanna Vaschetto; Marco Quaglia; Massimiliano Garzaro; Sergio Gentilli; Paolo Navalesi; Vincenzo Cantaluppi; Umberto Dianzani; Anna Aspesi; Annalisa Chiocchetti
Journal:  Mediators Inflamm       Date:  2017-07-09       Impact factor: 4.711

Review 5.  Hypoxia and its therapeutic possibilities in paediatric cancers.

Authors:  Carolina Bernauer; Y K Stella Man; Julia C Chisholm; Elise Y Lepicard; Simon P Robinson; Janet M Shipley
Journal:  Br J Cancer       Date:  2020-10-27       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.